Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $38 to $33.
Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $38 to $33.